The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2021 | SF3B1 mutant MDS
David Sallman, MD, of the Moffitt Cancer Center, Tampa, FL, gives an overview of SF3B1 mutant myelodysplastic syndromes (MDS), their clinical implications and the International Working Group Proposal. Dr Sallman explains that SF3B1 is the only mutation recognized by multiple groups to have predictive value of survival outcomes in the absence of adverse risk mutations, and also explains that SF3B1 is definitive of a low-risk MDS subtype with favorable prognosis. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
